Illumina (ILMN) Optics for Genomics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics

ILMN 121.07

-1.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (13)	1/9/2002 8:59:36 AM
From: mopgcw	Read Replies (1) of 276

Illumina Signs Genotyping Services Agreement With Johns Hopkins Medical University SNP Scoring Service to Leverage Illumina's BeadArray(TM) Platform Technology SAN DIEGO--(BW HealthWire)--Jan. 8, 2002-- Illumina, Inc. announced today that it has signed a commercial agreement with Johns Hopkins Medical University, Institute of Genetic Medicine to provide single nucleotide polymorphism (SNP) genotyping services on a sample collection provided by the Institute. Under the terms of the agreement, Illumina will use its BeadArray technology to ``score,'' or determine the frequency of specified SNPs in the sample set. Illumina will also design functional assays for most of the SNP loci provided by the Institute. Further details about the agreement were not disclosed. ``Johns Hopkins is a world leader in the research of genetic factors associated with conditions such as cleft lip and palate and isolated craniosynostosis, and we're pleased to be able to directly support their groundbreaking research activities,'' stated Jay Flatley, Illumina President and CEO. ``Our genotyping service capacity has reached one million genotypes per day in a highly multiplexed environment, and we look forward to working collaboratively with Johns Hopkins and other organizations to speed the analysis and lower the cost of large genotyping studies.'' Illumina (Nasdaq: ILMN; www.illumina.com) is developing next-generation tools that will permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology will provide the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics. Illumina's technology will have applicability across a wide variety of industries beyond life sciences and pharmaceuticals, including agriculture, food, chemicals and petrochemicals.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next